Pharnext strengthens its ties with Néovacs to secure the next steps in its development
Retrieved on:
Sunday, January 22, 2023
Communication, Regulatory News Service, CET, Medtech, Research, CFO, Biotechnology, Patient, Degenerative disease, Confidentiality, Investment, FDA, Therapy, Sciences Po, EMA, Verney-Carron, Marketing, Neurodegeneration, Hugo, Security (finance), Pharmaceutical industry, Health insurance, Management, Euronext
Under the terms of the agreement, Néovacs could become a reference shareholder of Pharnext as of January 1, 2024.
Key Points:
- Under the terms of the agreement, Néovacs could become a reference shareholder of Pharnext as of January 1, 2024.
- This new financing agreement is a partial or total complement to the OCEANE-BSA financing granted by Global Tech Opportunities 13 ("GTO 13").
- However, Néovacs, through the trust managing its financing contract with Pharnext, has agreed to subscribe to the €1 million tranche scheduled for late December.
- It was unbelievable that the Company would find itself in difficulty and that is why Néovacs decided to support it.